EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

What Does the Future Hold for Biomarkers of Response to Extracorporeal Photopheresis for Mycosis Fungoides and Sézary Syndrome?

Oleg E Akilov iD

Cells · 2023

DOI: 10.3390/cells12182321 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cells, 2023. Verfasst von Oleg E Akilov. Beteiligte Einrichtung: Cutaneous Lymphoma Program, University of Pittsburgh, Pittsburgh, PA 15213, USA. Hauptthemen laut MEDLINE: Sezary Syndrome, Photopheresis, Skin Neoplasms, Mycosis Fungoides. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Mallinckrodt.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Extracorporeal photopheresis (ECP) is an FDA-approved immunotherapy for cutaneous T-cell lymphoma, which can provide a complete response in some patients. However, it is still being determined who will respond well, and predictive biomarkers are urgently needed to target patients for timely treatment and to monitor their response over time. The aim of this review is to analyze the current state of the diagnostic, prognostic, and disease state-monitoring biomarkers of ECP, and outline the future direction of the ECP biomarker discovery. Specifically, we focus on biomarkers of response to ECP in mycosis fungoides and Sézary syndrome. The review summarizes the current knowledge of ECP biomarkers, including their limitations and potential applications, and identifies key challenges in ECP biomarker discovery. In addition, we discuss emerging technologies that could revolutionize ECP biomarker discovery and accelerate the translation of biomarker research into clinical practice. This review will interest researchers and clinicians seeking to optimize ECP therapy for cutaneous T-cell lymphoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sezary SyndromePhotopheresisSkin NeoplasmsMycosis FungoidesLymphoma, T-Cell, CutaneousHumansTreatment OutcomeBiomarkers

Stichwörter der Autor:innen

ECPSézary syndromebiomarkerextracorporeal photopheresismycosis fungoides

Substanzen

Biomarkers

Autor:innen und Institutionen

  • Cutaneous Lymphoma Program, University of Pittsburgh, Pittsburgh, PA 15213, USA.

ORCID-Profile: Oleg E Akilov

Förderung

  • Mallinckrodt

Zitieren

APA

Akilov, O. E. (2023). What Does the Future Hold for Biomarkers of Response to Extracorporeal Photopheresis for Mycosis Fungoides and Sézary Syndrome?. Cells. https://doi.org/10.3390/cells12182321

Vancouver

Akilov OE. What Does the Future Hold for Biomarkers of Response to Extracorporeal Photopheresis for Mycosis Fungoides and Sézary Syndrome?. Cells. 2023. doi:10.3390/cells12182321

BibTeX
@article{Akilov2023,
  author = {Akilov, Oleg E},
  title = {What Does the Future Hold for Biomarkers of Response to Extracorporeal Photopheresis for Mycosis Fungoides and Sézary Syndrome?},
  journal = {Cells},
  year = {2023},
  doi = {10.3390/cells12182321}
}
Kostenlos starten →